Maciej Zamek-Gliszczynski
Maciej Zamek-Gliszczynski
Senior Fellow and Director, Drug Metabolism and Pharmacokinetics, GlaxoSmithKline
Потвърден имейл адрес: gsk.com
Membrane transporters in drug development
KM Giacomini, SM Huang, DJ Tweedie, LZ Benet, KLR Brouwer, X Chu, ...
Nature Reviews Drug Discovery 9 (3), 215-236, 2010
Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites
MJ Zamek-Gliszczynski, KA Hoffmaster, K Nezasa, MN Tallman, ...
European journal of pharmaceutical sciences 27 (5), 447-486, 2006
Why Clinical Inhibition of Efflux Transport at the Blood-Brain Barrier is Unlikely: The ITC Evidence-Based Position
JC Kalvass, JW Polli, DL Bourdet, B Feng, SM Huang, X Liu, QR Smith, ...
Clinical Pharmacology & Therapeutics, 2013
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport‐mediated PK and DDIs in humans
MJ Zamek‐Gliszczynski, CA Lee, A Poirier, J Bentz, X Chu, H Ellens, ...
Clinical Pharmacology & Therapeutics 94 (1), 64-79, 2013
Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance
MJ Zamek‐Gliszczynski, ME Taub, PP Chothe, X Chu, KM Giacomini, ...
Clinical Pharmacology & Therapeutics 104 (5), 890-899, 2018
Pharmacokinetics of 5 (and 6)-carboxy-2′, 7′-dichlorofluorescein and its diacetate promoiety in the liver
MJ Zamek-Gliszczynski, H Xiong, NJ Patel, RZ Turncliff, GM Pollack, ...
Journal of Pharmacology and Experimental Therapeutics 304 (2), 801-809, 2003
Clinical probes and endogenous biomarkers as substrates for transporter drug‐drug interaction evaluation: perspectives from the international transporter consortium
X Chu, M Liao, H Shen, K Yoshida, AA Zur, V Arya, A Galetin, ...
Clinical Pharmacology & Therapeutics 104 (5), 836-864, 2018
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction …
CA Lee, MA O’Connor, TK Ritchie, A Galetin, JA Cook, ...
Drug metabolism and disposition 43 (4), 490-509, 2015
Evaluation of the role of multidrug resistance-associated protein (Mrp) 3 and Mrp4 in hepatic basolateral excretion of sulfate and glucuronide metabolites of acetaminophen, 4 …
MJ Zamek-Gliszczynski, K Nezasa, X Tian, AS Bridges, K Lee, ...
Journal of Pharmacology and Experimental Therapeutics 319 (3), 1485-1491, 2006
Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models
SB Peng, X Zhang, D Paul, LM Kays, W Gough, J Stewart, MT Uhlik, ...
Molecular cancer therapeutics 14 (2), 480-490, 2015
The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice
MJ Zamek-Gliszczynski, K Nezasa, X Tian, JC Kalvass, NJ Patel, TJ Raub, ...
Molecular pharmacology 70 (6), 2127-2133, 2006
Ablation of both organic cation transporter (OCT) 1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics
JW Higgins, DW Bedwell, MJ Zamek-Gliszczynski
Drug metabolism and disposition 40 (6), 1170-1177, 2012
Highlights from the International Transporter Consortium Second Workshop
MJ Zamek-Gliszczynski, KA Hoffmaster, DJ Tweedie, KM Giacomini, ...
Clinical Pharmacology & Therapeutics 92 (5), 553-556, 2012
Importance of hepatic transporters in clinical disposition of drugs and their metabolites
M Patel, KS Taskar, MJ Zamek‐Gliszczynski
The Journal of Clinical Pharmacology 56, S23-S39, 2016
The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
IH Song, J Zong, J Borland, F Jerva, B Wynne, MJ Zamek-Gliszczynski, ...
Journal of Acquired Immune Deficiency Syndromes (1999) 72 (4), 400, 2016
Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 Knockout Rats Using Loperamide, Paclitaxel, Sulfasalazine, and Carboxydichlorofluorescein Pharmacokinetics
MJ Zamek-Gliszczynski, DW Bedwell, JQ Bao, JW Higgins
Drug Metabolism and Disposition 40 (9), 1825-1833, 2012
Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat
MJ Zamek-Gliszczynski, KA Hoffmaster, JE Humphreys, X Tian, K Nezasa, ...
Journal of Pharmacology and Experimental Therapeutics 319 (1), 459-467, 2006
Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1
MJ Zamek-Gliszczynski, KA Hoffmaster, X Tian, R Zhao, JW Polli, ...
Drug metabolism and disposition 33 (8), 1158-1165, 2005
A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer
S Pant, SF Jones, CD Kurkjian, JR Infante, KN Moore, HA Burris, ...
European journal of cancer 56, 1-9, 2016
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin …
JW Higgins, JQ Bao, AB Ke, JR Manro, JK Fallon, PC Smith, ...
Drug Metabolism and Disposition 42 (1), 182-192, 2014
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20